Difference between revisions of "Congestive heart failure"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 272: Line 272:
 
(.//.)<html><!--Pop-up for: Degeneration of sinoatrial ganglion !Pop-up-->
 
(.//.)<html><!--Pop-up for: Degeneration of sinoatrial ganglion !Pop-up-->
 
<div class="1J10YG1FK-B3ZV95-46X" style="display:none;">
 
<div class="1J10YG1FK-B3ZV95-46X" style="display:none;">
 +
  
  
Line 283: Line 284:
 
</div>(...)<!--Pop-up for: Impaired myocardial  Respiration and nutrition !Pop-up-->
 
</div>(...)<!--Pop-up for: Impaired myocardial  Respiration and nutrition !Pop-up-->
 
<div class="1J10Y7YTV-2DZGSP7-3YF" style="display:none;">
 
<div class="1J10Y7YTV-2DZGSP7-3YF" style="display:none;">
 +
  
  
Line 294: Line 296:
 
</div>(...)<!--Pop-up for: Cardiomyocyte apoptosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Cardiomyocyte apoptosis !Pop-up-->
 
<div class="1J10XMCBH-1RXH7GQ-359" style="display:none;">
 
<div class="1J10XMCBH-1RXH7GQ-359" style="display:none;">
 +
  
  
Line 305: Line 308:
 
</div>(...)<!--Pop-up for: Reduced baroreflex !Pop-up-->
 
</div>(...)<!--Pop-up for: Reduced baroreflex !Pop-up-->
 
<div class="1J10YFGND-FDTZ7S-45Z" style="display:none;">
 
<div class="1J10YFGND-FDTZ7S-45Z" style="display:none;">
 +
  
  
Line 316: Line 320:
 
</div>(...)<!--Pop-up for: Growth of peripheral vascular resistance !Pop-up-->
 
</div>(...)<!--Pop-up for: Growth of peripheral vascular resistance !Pop-up-->
 
<div class="1J10YJ29C-ZWBZG-4FP" style="display:none;">
 
<div class="1J10YJ29C-ZWBZG-4FP" style="display:none;">
 +
  
  
Line 327: Line 332:
 
</div>(...)<!--Pop-up for: Left ventricular hypertrophy !Pop-up-->
 
</div>(...)<!--Pop-up for: Left ventricular hypertrophy !Pop-up-->
 
<div class="1J10YZ5L3-16PC1J2-52C" style="display:none;">
 
<div class="1J10YZ5L3-16PC1J2-52C" style="display:none;">
 +
  
  
Line 338: Line 344:
 
</div>(...)<!--Pop-up for: Transthyretin  amyloidosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Transthyretin  amyloidosis !Pop-up-->
 
<div class="1J10XNZSM-Y1XLC8-38C" style="display:none;">
 
<div class="1J10XNZSM-Y1XLC8-38C" style="display:none;">
 +
  
  
Line 349: Line 356:
 
</div>(...)<!--Pop-up for: Atherosclerosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Atherosclerosis !Pop-up-->
 
<div class="1N9H64WCF-XHZP2C-1K7W" style="display:none;">
 
<div class="1N9H64WCF-XHZP2C-1K7W" style="display:none;">
 +
  
  
Line 360: Line 368:
 
</div>(...)<!--Pop-up for: Reduced sensitivity to  Beta-adrenergic stimulation !Pop-up-->
 
</div>(...)<!--Pop-up for: Reduced sensitivity to  Beta-adrenergic stimulation !Pop-up-->
 
<div class="1J10YCZ3L-15SBWYY-43R" style="display:none;">
 
<div class="1J10YCZ3L-15SBWYY-43R" style="display:none;">
 +
  
  
Line 371: Line 380:
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
<div class="1J10XN5W9-NKHBMH-36P" style="display:none;">
 
<div class="1J10XN5W9-NKHBMH-36P" style="display:none;">
 +
  
  
Line 382: Line 392:
 
</div>(...)<!--Pop-up for: Exercise intolerance !Pop-up-->
 
</div>(...)<!--Pop-up for: Exercise intolerance !Pop-up-->
 
<div class="1J10Y3XC0-9Q4KHS-3SQ" style="display:none;">
 
<div class="1J10Y3XC0-9Q4KHS-3SQ" style="display:none;">
 +
  
  
Line 393: Line 404:
 
</div>(...)<!--Pop-up for: Coronary blood flow violation !Pop-up-->
 
</div>(...)<!--Pop-up for: Coronary blood flow violation !Pop-up-->
 
<div class="1J10Y7DR9-Y4Z0YM-3X2" style="display:none;">
 
<div class="1J10Y7DR9-Y4Z0YM-3X2" style="display:none;">
 +
  
  
Line 404: Line 416:
 
</div>(...)<!--Pop-up for: Interstitial  Myocardial fibrosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Interstitial  Myocardial fibrosis !Pop-up-->
 
<div class="1J10ZSRS9-1V0D2WY-5RF" style="display:none;">
 
<div class="1J10ZSRS9-1V0D2WY-5RF" style="display:none;">
 +
  
  
Line 415: Line 428:
 
</div>(...)<!--Pop-up for: Deterioration  Of blood rheology !Pop-up-->
 
</div>(...)<!--Pop-up for: Deterioration  Of blood rheology !Pop-up-->
 
<div class="1J10YPR9Q-1C2LGV-4PR" style="display:none;">
 
<div class="1J10YPR9Q-1C2LGV-4PR" style="display:none;">
 +
  
  
Line 426: Line 440:
 
</div>(...)<!--Pop-up for: Emotional stress !Pop-up-->
 
</div>(...)<!--Pop-up for: Emotional stress !Pop-up-->
 
<div class="1J10XWBKM-S8PP5S-3DR" style="display:none;">
 
<div class="1J10XWBKM-S8PP5S-3DR" style="display:none;">
 +
  
  
Line 437: Line 452:
 
</div>(...)<!--Pop-up for: Coronary arteriosclerosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Coronary arteriosclerosis !Pop-up-->
 
<div class="1J10Y96V3-SR8S5J-411" style="display:none;">
 
<div class="1J10Y96V3-SR8S5J-411" style="display:none;">
 +
  
  
Line 448: Line 464:
 
</div>(...)<!--Pop-up for: Congestion in lungs and systemic circulation !Pop-up-->
 
</div>(...)<!--Pop-up for: Congestion in lungs and systemic circulation !Pop-up-->
 
<div class="1J10ZDVQT-FKGKY8-58R" style="display:none;">
 
<div class="1J10ZDVQT-FKGKY8-58R" style="display:none;">
 +
  
  
Line 459: Line 476:
 
</div>(...)<!--Pop-up for: Adrenaline oxidation !Pop-up-->
 
</div>(...)<!--Pop-up for: Adrenaline oxidation !Pop-up-->
 
<div class="1J10XWLKS-16Z5NKX-3F4" style="display:none;">
 
<div class="1J10XWLKS-16Z5NKX-3F4" style="display:none;">
 +
  
  
Line 470: Line 488:
 
</div>(...)<!--Pop-up for: Lipofuscin !Pop-up-->
 
</div>(...)<!--Pop-up for: Lipofuscin !Pop-up-->
 
<div class="1J10XNHFJ-T2HHRP-37G" style="display:none;">
 
<div class="1J10XNHFJ-T2HHRP-37G" style="display:none;">
 +
  
  
Line 481: Line 500:
 
</div>(...)<!--Pop-up for: Increased  Sympathetic stimulation  Of vasoconstriction !Pop-up-->
 
</div>(...)<!--Pop-up for: Increased  Sympathetic stimulation  Of vasoconstriction !Pop-up-->
 
<div class="1J10YKQ3S-16TQZKP-4J1" style="display:none;">
 
<div class="1J10YKQ3S-16TQZKP-4J1" style="display:none;">
 +
  
  
Line 492: Line 512:
 
</div>(...)<!--Pop-up for: Left ventricular dysfunction  !Pop-up-->
 
</div>(...)<!--Pop-up for: Left ventricular dysfunction  !Pop-up-->
 
<div class="1J10ZXCLY-1FKQLSB-642" style="display:none;">
 
<div class="1J10ZXCLY-1FKQLSB-642" style="display:none;">
 +
  
  
Line 503: Line 524:
 
</div>(...)<!--Pop-up for: Reduced elasticity of vessel walls !Pop-up-->
 
</div>(...)<!--Pop-up for: Reduced elasticity of vessel walls !Pop-up-->
 
<div class="1J10YNZT6-XRQHD7-4NC" style="display:none;">
 
<div class="1J10YNZT6-XRQHD7-4NC" style="display:none;">
 +
  
  
Line 514: Line 536:
 
</div>(...)<!--Pop-up for: Reduced synthesis of  Vascular endothelium vasodilatation  Factors !Pop-up-->
 
</div>(...)<!--Pop-up for: Reduced synthesis of  Vascular endothelium vasodilatation  Factors !Pop-up-->
 
<div class="1J10YM53W-TSMD9Q-4KX" style="display:none;">
 
<div class="1J10YM53W-TSMD9Q-4KX" style="display:none;">
 +
  
  
Line 525: Line 548:
 
</div>(...)<!--Pop-up for: Hypoxia of organs and tissues !Pop-up-->
 
</div>(...)<!--Pop-up for: Hypoxia of organs and tissues !Pop-up-->
 
<div class="1J10ZH90X-1HBHY7Z-5C6" style="display:none;">
 
<div class="1J10ZH90X-1HBHY7Z-5C6" style="display:none;">
 +
  
  
Line 536: Line 560:
 
</div>(...)<!--Pop-up for: Cytotoxic quinones !Pop-up-->
 
</div>(...)<!--Pop-up for: Cytotoxic quinones !Pop-up-->
 
<div class="1J10XXRJP-1JGC30W-3GN" style="display:none;">
 
<div class="1J10XXRJP-1JGC30W-3GN" style="display:none;">
 +
  
  
Line 547: Line 572:
 
</div>(...)<!--Pop-up for: Mitochondrial dysfunction !Pop-up-->
 
</div>(...)<!--Pop-up for: Mitochondrial dysfunction !Pop-up-->
 
<div class="1J10Y5XY5-28LG6Z6-3V2" style="display:none;">
 
<div class="1J10Y5XY5-28LG6Z6-3V2" style="display:none;">
 +
  
  
Line 558: Line 584:
 
</div>(...)<!--Pop-up for: Brown atrophy of myocardium !Pop-up-->
 
</div>(...)<!--Pop-up for: Brown atrophy of myocardium !Pop-up-->
 
<div class="1J10XTZZH-1NX2X4L-3CM" style="display:none;">
 
<div class="1J10XTZZH-1NX2X4L-3CM" style="display:none;">
 +
  
  
Line 569: Line 596:
 
</div>(...)<!--Pop-up for: Congestive heart failure !Pop-up-->
 
</div>(...)<!--Pop-up for: Congestive heart failure !Pop-up-->
 
<div class="1J10Y117F-XWK7P7-3PH" style="display:none;">
 
<div class="1J10Y117F-XWK7P7-3PH" style="display:none;">
 +
  
  
Line 580: Line 608:
 
</div>(...)<!--Pop-up for: Acidosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Acidosis !Pop-up-->
 
<div class="1J10ZHYDN-NGZTB1-5DM" style="display:none;">
 
<div class="1J10ZHYDN-NGZTB1-5DM" style="display:none;">
 +
  
  

Latest revision as of 09:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Congestive heart failure

Congestive heart failure (CHF) is a state of abnormal cardiac function. CHF is not a single entity but a symptom complex that may represent the consequence of mechanical abnormalities, myocardial abnormalities, and/or disturbances of cardiac rhythm. In turn, it affects virtually every organ system in the body. Congestive heart failure is a common clinical syndrome. In the US, there are approximately 4.8 million patients with congestive heart failure. The incidence and prevalence increases with increasing age and it has been estimated that 1.5% of all adults and 6 to 10% of adults aged more than age 65 years have congestive heart failure.

The most frequent causes for heart failure are myocardial infarction, pressure overload, volume overload, viral myocarditis, toxic cardiomyopathy and mutations in genes encoding for sarcomeric or cytoskeletal proteins. Myocardial damage with subsequent neurohumoral and cytokine activation induce chamber remodeling and phenotype alteration which then result in myocardial failure.

Although there is no single unifying pathogenetic theory, a number of biochemical abnormalities have been described in heart failure. There is agreement that the efficiency of the heart as a pump is reduced in the low-output, systolic heart failure that occurs in ischemic heart disease and dilated cardiomyopathy. The “external work” performed by the left ventricle is depressed, whereas its energy consumption is normal or almost so.15 Thus, the dilated, failing heart is energy-inefficient. Second, alterations in cardiac energy metabolism are frequently observed in systolic heart failure. Relative ischemia of the subendocardium occurs in ventricular hypertrophy and dilatation.

Congestive heart failure (CHF) promotes an array of biologic changes that are largely designed to compensate for reduced flow. These include activation of the sympathetic nervous system and the renin-angiotensin system, as well as the release of arginine vasopressin. The ultimate expression of these compensatory mechanisms is heightened vascular tone, increased sodium and water retention and antidiuresis. The peripheral circulation is normally under the fine control of circulating and neuronally released moieties, which can directly or indirectly alter vascular tone. Angiotensin II appears to be a key element in this regard because of its multiple biologic activities. Direct arteriolar vasoconstriction, facilitation of norepinephrine release and stimulation of aldosterone are some of the activities that are likely to be of major importance in the syndrome of CHF.